HIV-1 gp41, aa466-753, Recombinant (Human Immunodeficiency Virus-1)

The protein contains the a 32kD fragment of HIV-I glycoprotein gp41, amino acids: (466-753).\n\nSpecificity:\nImmunoreactive with all sera of HIV-I infected individuals.\n\nApplications:\nAntigen in ELISA and Western Blot, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, store at -20 degrees C. Aliquots are stable for at least 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

H6003-02B

Size

100ug

Form

Supplied as a liquid in 20mM PBS, pH 7.8, 20mM sodium chloride, 1mM DTT, 8M urea.

Purity

(same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. Devito C, Zuber B, Benthin R, Hinkula J, J Immunol 2004 Dec 1;173(11):7078-89 2. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Hovanessian AG, Briand JP, Svab J, Desgranges C, Immunity 2004 Nov;21(5):617-27 3. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. Zhang H, Huang Y, Spear GT, J Virol 2004 Aug;78(15):8342-8 4. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. Gallo SA, Clore GM, Bewley CA, Biochemistry 2004 Jun 29;43(25):8230-3 5. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Liu S, Jiang S, Curr Pharm Des 2004;10(15):1827-43 6. HIV-1 gp41 as a target for viral entry inhibition. Root MJ, Steger HK, Curr Pharm Des 2004;10(15):1805-25.